| 24.02 -0.39 (-1.6%) | 01-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 30.85 | 1-year : | 33.93 |
| Resists | First : | 26.41 | Second : | 29.04 |
| Pivot price | 24.75 |
|||
| Supports | First : | 22.16 | Second : | 18.44 |
| MAs | MA(5) : | 24.21  |
MA(20) : | 24.89 |
| MA(100) : | 29.62 |
MA(250) : | 35.01 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 29.8 |
D(3) : | 30.7 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 53.18 | Low : | 22.16 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLDX ] has closed above bottom band by 37.7%. Bollinger Bands are 9.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.61 - 24.73 | 24.73 - 24.83 |
| Low: | 23.52 - 23.65 | 23.65 - 23.75 |
| Close: | 23.83 - 24.03 | 24.03 - 24.2 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Wed, 22 Jan 2025
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - MSN
Wed, 22 Jan 2025
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Mon, 20 Jan 2025
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expands By 10.7% - MarketBeat
Wed, 20 Nov 2024
Insider Spends US$308k Buying More Shares In Celldex Therapeutics - Simply Wall St
Wed, 13 Nov 2024
FMR LLC's Strategic Reduction in Celldex Therapeutics Inc Shares - GuruFocus.com
Mon, 11 Nov 2024
Celldex (CLDX) to Present at Two Major Healthcare Investor Conferences in Q4 - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 6.616e+007 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 7,830 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7106e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 633.5 % |
| Return on Equity (ttm) | -19.8 % |
| Qtrly Rev. Growth | 9.98e+006 % |
| Gross Profit (p.s.) | 69.37 |
| Sales Per Share | -18.77 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -158 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.28 |
| Price to Cash Flow | 3.22 |
| Dividend | 0 |
| Forward Dividend | 7.31e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|